Cosmos Health Inc. (COSM) Stock Price & Analysis
Cosmos Health Inc. (COSM) fell 2.91% to USD 0.22 as of June 10, 2026 at 04:02 UTC, according to Nexqual real-time market data.
COSM last closed at USD 0.23; the session ranged USD 0.21–0.26 on volume of 5,285,048 shares. Market capitalization is $13.86M, with a 52-week range of USD 0.21–1.32 (NCM). Source: Nexqual, June 10, 2026 at 04:02 UTC.
Key Statistics (as of June 10, 2026 at 04:02 UTC)
| Price | USD 0.22 |
|---|---|
| Change | ▼ 2.91% (down) |
| Previous Close | USD 0.23 |
| Open | USD 0.23 |
| Day Range | USD 0.21 – 0.26 |
| 52-Week Range | USD 0.21 – 1.32 |
| Volume | 5,285,048 shares |
| Market Cap | $13.86M |
| Exchange | NCM |
Technical Analysis (COSM)
Nexqual's technical model rates COSM "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 04:02 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 33.13 (neutral) |
| vs SMA50 | Below (USD 0.32) |
| MACD | -0.02 (negative) |
Analyst Ratings (COSM)
Wall Street analysts rate COSM "Strong Buy" based on 1 analysts, with a mean price target of USD 4.5 (range USD 4.5–4.5), per Nexqual as of June 10, 2026 at 04:02 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 4.5 |
| High Target | USD 4.5 |
| Low Target | USD 4.5 |
| Buy / Hold / Sell | 0 / 0 / 0 |
Earnings (COSM)
| Revenue Estimate | $19.72M |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.03 vs est -0.01 ▼ miss |
| 2025-12-31 | USD -0.36 vs est -0.04 ▼ miss |
Source: Nexqual, June 10, 2026 at 04:02 UTC.
Financials & Fundamentals (COSM)
| Total Revenue | $69.49M |
|---|---|
| Revenue Growth (YoY) | +30.70% |
| Gross Margin | +10.40% |
| Operating Margin | -12.18% |
| Profit Margin | -30.41% |
| ROE | -92.32% |
| Debt / Equity | 87.87 |
| Current Ratio | 1.08 |
| Total Cash | $548,927 |
| Total Debt | $17.42M |
| Free Cash Flow | $-11.26M |
Source: Nexqual, June 10, 2026 at 04:02 UTC.
Financial Health Score (COSM)
Nexqual rates Cosmos Health Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 04:02 UTC.
| Growth | Strong — Revenue +31% YoY (latest Q) |
|---|---|
| Profitability | Critical — Gross margin 10%, operating -12% |
| Balance Sheet | Mixed — $549K cash vs $17M debt |
| Cash Flow | Weak — FCF negative: -$11M, burning cash |
| Efficiency | Critical — ROE -92%, ROA -18.7% |
Ownership (COSM)
| Insider Ownership | +32.17% |
|---|---|
| Institutional Ownership | +5.10% |
| Shares Outstanding | 62.08M |
| Float | 40.26M |
| Short % of Float | +1.98% |
Source: Nexqual, June 10, 2026 at 04:02 UTC.
Leadership (COSM)
Cosmos Health Inc. is led by Grigorios Siokas (age 60), Chairman & CEO, per Nexqual as of June 10, 2026 at 04:02 UTC.
| Chairman & CEO | Grigorios Siokas (age 60) |
|---|---|
| Chief Financial Officer | Georgios Terzis (age 42) |
| Chief Operating Officer | Nikolaos Bardakis (age 56) |
| Secretary & Independent Director | Demetrios G. Demetriades (age 60) |
Major Backers & Investors (COSM)
Notable institutional backers of Cosmos Health Inc. include Renaissance Technologies, Fidelity, HRT Financial LP, according to Nexqual as of June 10, 2026 at 04:02 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Renaissance Technologies | 0.65% |
| Fidelity | 0.47% |
| HRT Financial LP | 0.11% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.62% |
| Geode Capital | 0.53% |
| BlackRock | 0.45% |
Source: Nexqual, June 10, 2026 at 04:02 UTC.
From Cosmos Health Inc.'s Latest SEC 10-K Filing (filed 2026-04-15)
Key Strengths & Strategy (as disclosed to the SEC)
- We also seek to continually enhance the organizational effectiveness of all of our functions, including efforts to accurately and ethically launch and promote our products.   Information Systems   Our wholesale operations are managed through a primary enterprise resource planning ("ERP") system, which supports key functions including electronic order entry by customers, invoice processing, purchasing, and inventory tracking.
- While nutraceuticals are not classified as drugs, they are often used for their therapeutic effects in a manner similar to pharmaceuticals.   Our proprietary nutraceutical brands are Sky Premium Life® ("SPL") and Mediterranation®.
- Our portfolio currently includes around 165 SKUs and more specifically product codes such as Vitamins and Minerals, Amino Acids, Botanical and other Herbal extracts used for health prevention and care needs.     Our products are classified into two main categories, "Products per Benefit" and "Products per Nutrient" as follows:       Biocides   Our proprietary portfolio of branded biocides and antiseptic soaps comprises of our brands C-Sept® and C-Scrub®.
- Especially for high-cost conditions like cancer, exploring anti-cancer potentials in a vast array of off-patent drugs, which have already established their safety profiles, is a powerful tactic preferred by most leading pharmaceutical enterprises.   We have built on promising preclinical discoveries, predictive insights, and simulations generated by Cosmos Health's AI-powered Cloudscreen® drug repurposing platform.
Partnerships
- GDPR applies to the processing of personal data of persons in the EU by a controller or processor.     Research and Development   The Company entered into a Research & Development agreement with Doc Pharma S.A. on May 17, 2021.
- Thus, no relevant R&D expense had been charged to the Company's Consolidated Statements of Operations and Comprehensive Loss, concerning this agreement.   On June 25, 2022, the Company signed a research and development ("R&D") agreement with a third party (CloudPharm PC), through which the Company assigned to the third party the development of new products and services in the field of health, focusing on the human intestinal microbiome.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GNS | Genius Group Limited | USD 0.23 | ▼ 5.37% |
| DBGI | Digital Brands Group, Inc. | USD 1.07 | ▲ 24.42% |
| PXMD | PaxMedica, Inc. | USD 0 | ▲ 0% |
| MSGM | Motorsport Games Inc. | USD 4.23 | ▲ 1.2% |
| PALI | Palisade Bio, Inc. | USD 1.69 | ▼ 2.87% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:02 UTC. This page is informational and not investment advice.